Clinical Trial NCT04965597

Trial

Fred Hutchinson Cancer Center – BMTCTN1904

Clinical trial ID

NCT04965597

Drug name

Treosulfan, Fludarabine and rATG

Company:

Fred Hutchinson Cancer Center

Drug trade name

---

Phase of study

2

Current status

Recruiting

Start

04/2022

Substance

cytostatics, cytotoxines and antibodies

Research question

---

Delivery method of drug

i.v.

Frequency

6 days daily until transplantation, following 180 days of prophylaxis

Clinical trial locations

USA